Virtus Biotech ETF (BBP) |
| 86.6124 2.066 (2.44%) 06-04 15:53 |
| Open: | 85.69 |
| High: | 86.905 |
| Low: | 85.69 |
| Volume: | 4,461 |
| Market Cap: | 35(M) |
| PE Ratio: | 0 |
| Exchange: | New York Stock Exchange Arca |
| Industry: | Asset Management |
| Sector: | Financial Services |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 105.61 |
| Resistance 1: | 90.42 |
| Pivot price: | 85.92 |
| Support 1: | 85.69 |
| Support 2: | 82.76 |
| 52w High: | 90.42 |
| 52w Low: | 57.61 |
The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index, which tracks the performance of biotechnology companies with at least one drug therapy approved by the FDA.Effective February 27, this Fund's name changed from Virtus LifeSci Biotech Products ETF to Virtus Biotech ETF.
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Wed, 27 May 2026
5 Small-cap Biotech ETFs to Watch in 2026 - Investing News Network
Wed, 20 May 2026
ImmunityBio Stock Climbs As FDA Accepts Expanded Use Filing For Bladder Cancer Drug - Benzinga
Thu, 14 May 2026
BBP | Virtus Biotech ETF Insider Trading - Quiver Quantitative
Wed, 03 Sep 2025
Contrarian Investing in US Stocks: These ETFs Are Timely Picks - NAI500
Tue, 20 Sep 2022
Innovation Reigns In 10 Best-Performing ETFs Of The Last 3 Months - FA Mag
Fri, 05 Aug 2022
Biotech ETFs Rally as Global Blood Therapeutics Surges on Potential Pfizer Deal - ETF Trends
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
